FDA Reposts Warning About Pregnancy-Related Risks Associated With Organ Transplant Drugs

Main Category: Pregnancy / Obstetrics
Also Included In: Transplants / Organ Donations
Article Date: 21 May 2008 - 7:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  


Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


FDA on Friday reposted a notice warning that Roche and Novartis drugs prescribed for organ transplant recipients could cause miscarriages and birth defects when used by pregnant women and urged doctors to confirm that transplant patients are not pregnant and are using effective contraception, the AP/Google.com reports. Roche's CellCept and Novartis' Myfortic are used to suppress the body's immune system to avoid organ rejection in people undergoing transplant surgery.

FDA first issued the warning in October 2007. Agency spokesperson Christopher Kelly said that FDA has not received any new reports of pregnancy-related complications but that it was concerned that some physicians might not have seen the initial warning. FDA said most of the reported problems came from women who were taking CellCept before they knew they were pregnant. Some of the women were taking the drug for conditions it was not approved to treat, including rheumatoid arthritis and lupus. A spokesperson for Roche said the company has not received any new reports of miscarriages or birth defects since updating the drug's labeling (Perrone, AP/Google.com, 5/16).

When FDA issued the initial warning, it cited National Transplantation Pregnancy Registry data published in December 2006 of 24 women exposed to CellCept. The women had a total of 33 pregnancies, of which 15 resulted in a miscarriage and 18 in a live birth. Among the 18 live births, four infants had birth defects. According to postmarketing data, which were collected by Roche and involved 77 women who took CellCept, there were 25 miscarriages and 14 birth defects among fetuses and infants (Daily Women's Health Policy Report, 10/31/07).

Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women's Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women's Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company.

© 2008 The Advisory Board Company. All rights reserved.

View drug information on CellCept.


Article adapted by Medical News Today from original press release.
Visit our pregnancy / obstetrics section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
National Partnership for Women & Families. "FDA Reposts Warning About Pregnancy-Related Risks Associated With Organ Transplant Drugs." Medical News Today. MediLexicon, Intl., 21 May. 2008. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/108178.php>

APA
National Partnership for Women & Families. (2008, May 21). "FDA Reposts Warning About Pregnancy-Related Risks Associated With Organ Transplant Drugs." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/108178.php.

Please note: If no author information is provided, the source is cited instead.




Pregnancy / Obstetrics

Most Popular Articles



Follow Our Pregnancy News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Pregnancy / Obstetrics Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »